Carbetocin in the prevention of postpartum hemorrhage
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252728Keywords:
Carbetocin, Lower segment cesarean section, Postpartum hemorrhage , Uterine tone, Vaginal deliveryAbstract
Background: Postpartum hemorrhage (PPH) is the most common and a potentially life-threatening complication of childbirth in both vaginal and caesarean deliveries. Carbetocin is a newer analogue of oxytocin with longer half-life and more heat stable. This study was aimed to assess the efficacy of carbetocin in the prevention of postpartum hemorrhage (PPH) in vaginal and caesarean deliveries, at a single tertiary care centre.
Methods: A total of 130 pregnant patients included in the study received a bolus of carbetocin 100 µg i.v./i.m. at the delivery of anterior shoulder. After patients received uterotonic agent (carbetocin), patients were observed for 24 hours. The change in hemodynamic and clinical variables such as drop in hematocrit than one obtained on admission was observed. Clinical signs such as pallor, cold clammy skin, hypotension and tachycardia were also noted. In addition uterine tone after receiving carbetocin was also noted.
Results: There were comparable hemodynamic parameters in terms of heart rate, SBP and DBP in the pre-labor and post-labor. Most of the patients 54.6% (n=71) had contracted uterine tone followed by well-contracted in 35.4% (n=46). There was no significant difference found in terms of hemoglobin concentration and hematocrit in pre-labor and post-labor. 3.1% (n=4) patients experienced PPH. 6.15% (n=8) needed blood transfusion. No adverse effects or complications or maternal mortality was observed in the present study.
Conclusions: This study concludes that using carbetocin in the third stage of labour resulted in decreased incidence of post-partum hemorrhage, decreased blood transfusion as well as decreased use of additional uterotonics.
Metrics
References
PPH CPG Work Group. Pospartum Hemorrhage. (Clinical Practice Guideline 17). Toronto (ON): Association of Ontario Midwives; 2016: Available at: https://www.ontariomidwives.ca/sites/default/files/2017-12/CPG-Postpartum-hemorrahge-PUB_1.pdf. Accessed on 15 July 2019.
Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):323-33. DOI: https://doi.org/10.1016/S2214-109X(14)70227-X
WHO Postpartum Hemorrhage Summit. United Arab Emirates. 2023. Available at: https://www.who.int/news-room/events/detail/ 2023/03/07/default-calendar/who-postpartum-haemorrhage-summit. Accessed on 3 May 2025.
Changede P, Chavan N, Raj N, Gupta P. An observational study to evaluate the maternal and foetal outcomes in pregnancies complicated with jaundice. J Obstet Gynecol India. 2019;69(1):31-6. DOI: https://doi.org/10.1007/s13224-018-1105-9
Gillissen A, Van Den Akker T, Caram-Deelder C, Henriquez DD, Bloemenkamp KW, De Maat MP, et al. Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. Blood advances. 2018;2(19):2433-42. DOI: https://doi.org/10.1182/bloodadvances.2018022632
McDonald SJ. Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour. Cochrane database of systematic reviews. 2004;1:201. DOI: https://doi.org/10.1002/14651858.CD000201.pub2
Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev. 2007;1:3249. DOI: https://doi.org/10.1002/14651858.CD003249.pub2
Van Dongen PW, Verbruggen MM, De Groot AN, Van Roosmalen J, Sporken JM, Schulz M. Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. Eur J Obstet Gynecol Reprod Biol. 1998;77(2):181-7. DOI: https://doi.org/10.1016/S0301-2115(97)00260-1
Malm M, Madsen I, Kjellström J. Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle‐income countries. J Peptide Sci. 2018;24(6):3082. DOI: https://doi.org/10.1002/psc.3082
Amornpetchakul P, Lertbunnaphong T, Boriboonhiransarn D, Leetheeragul J, Sirisomboon R, Jiraprasertwong R. Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in high-risk singleton pregnancies: a triple-blind randomized controlled trial. Arch Gynecol Obstet. 2018;298(2):319-27.
Prevention and Management of Postpartum Hemorrhage: Green-top Guideline No. 52. BJOG. 2017;124(5):e106-49. DOI: https://doi.org/10.1111/1471-0528.14178
Amornpetchakul P, Lertbunnaphong T, Boriboonhiransarn D, Leetheeragul J, Sirisomboon R, Jiraprasertwong R. Intravenous carbetocin versus intravenous oxytocin for preventing atonic postpartum hemorrhage after normal vaginal delivery in high-risk singleton pregnancies: a triple-blind randomized controlled trial. Arch Gynecol Obstet. 2018;298(2):319-27. DOI: https://doi.org/10.1007/s00404-018-4806-5
Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B, et al. Carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. J Prenat Med. 2013;7(1):12. DOI: https://doi.org/10.11138/jpm/2013.7.1.012
Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-analysis of randomized controlled trials in cesarean deliveries. Taiwan J Obstet Gynecol. 2018;57(3):332-9. DOI: https://doi.org/10.1016/j.tjog.2018.04.002
van der Nelson H, O'Brien S, Burnard S, Mayer M, Alvarez M, Knowlden J, et al. Intramuscular oxytocin versus Syntometrine® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: a randomised double‐blinded clinical trial of effectiveness, side effects and quality of life. BJOG. 2021;128(7):1236-46. DOI: https://doi.org/10.1111/1471-0528.16622
Boucher M, Nimrod CA, Tawagi GF, Meeker TA, White RE, Varin J. Comparison of carbetocin and oxytocin for the prevention of postpartum hemorrhage following vaginal delivery: a double-blind randomized trial. J Obstet Gynecol Canada. 2004 May 1;26(5):481-8. DOI: https://doi.org/10.1016/S1701-2163(16)30659-4
Montgomery AL, Ram U, Kumar R, Jha P, Million Death Study Collaborators. Maternal mortality in India: causes and healthcare service use based on a nationally representative survey. PloS One. 2014;9(1):e83331. DOI: https://doi.org/10.1371/journal.pone.0083331
Korb D, Lopez R, Hörlin AL, Schmitz T, Borie C, Sibony O. Effectiveness of prophylactic carbetocin versus oxytocin following vaginal delivery for preventing severe postpartum hemorrhage. Int J Gynecol Obstet. 2023;162(3):889-94. DOI: https://doi.org/10.1002/ijgo.14743
Elgarhy EM, Mohamed AH, Abdelfatah MM. Carbetocin versus oxytocin in prevention of atonic postpartum hemorrhage. Al-Azhar Int Med J. 2020;1(9):265-9. DOI: https://doi.org/10.21608/aimj.2020.22559.1087
Bashir K, Sabha S. Carbetocin versus Oxytocin in placental separation and postpartum hemorrhage in caesarean section-comparative observational study. Int J Reprod Contracept Obstet Gynecol. 2023;12(7):2004-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20231791
Chen CY, Su YN, Lin TH, Chang Y, Horng HC, Wang PH, et al. Carbetocin in prevention of postpartum hemorrhage: experience in a tertiary medical center of Taiwan. Taiwan J Obstet Gynecol. 2016;55(6):804-9. DOI: https://doi.org/10.1016/j.tjog.2016.07.009
Liu H, Xu XY, Gu N, Ye XD, Wang ZQ, Hu YL, et al. Intravenous administration of carbetocin versus oxytocin for preventing postpartum hemorrhage after vaginal delivery in high risk women: a double-blind, randomized controlled trial. Matern Fet Med. 2020;2(02):72-9. DOI: https://doi.org/10.1097/FM9.0000000000000048
Anurag A, Singh S, Kumar S. Comparison of carbetocin and oxytocin in the prevention of atonic postpartum hemorrhage following normal vaginal delivery. Int J Reprod Contracept Obstet Gynecol. 2022;11:2665-8. DOI: https://doi.org/10.18203/2320-1770.ijrcog20222459
Abd El Aziz MA, Iraqi A, Abedi P, Jahanfar S. The effect of carbetocin compared to misoprostol in management of the third stage of labor and prevention of postpartum hemorrhage: a systematic review. Syst Rev. 2018;7(1):170. DOI: https://doi.org/10.1186/s13643-018-0832-4
Kang S, Zhou L, Zhu L, Wang Y, Yue Y, Yan L. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage after elective caesarean section in high risk women: a prospective, randomized, open-label, controlled trial in China. Clin Exp Obstet Gynecol. 2022;49(1):23. DOI: https://doi.org/10.31083/j.ceog4901023
Kalafat E, Gokce A, O’Brien P, Benlioglu C, Koc A, Karaaslan O, et al. Efficacy of carbetocin in the prevention of postpartum hemorrhage: a systematic review and Bayesian meta-analysis of randomized trials. J Matern Fet Neonat Med. 2021;34(14):2303-16. DOI: https://doi.org/10.1080/14767058.2019.1664463
Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol. 1999;180(3):670-6. DOI: https://doi.org/10.1016/S0002-9378(99)70271-1
Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after caesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009;280:707-12. DOI: https://doi.org/10.1007/s00404-009-0973-8
Rath W. Prevention of postpartum hemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):15-20. DOI: https://doi.org/10.1016/j.ejogrb.2009.06.018
Arif N, Tahir UA, Aftab K, Rasheed T, Chandio K. Efficacy and safety of carbetocin in prevention of postpartum hemorrhage. Pak J Med Health Sci. 2023;17(2):734. DOI: https://doi.org/10.53350/pjmhs2023172734
Maged AM, Hassan AM, Shehata NA. Carbetocin versus oxytocin for prevention of postpartum hemorrhage after vaginal delivery in high risk women. J Matern Fet Neonat Med. 2016;29(4):532-6. DOI: https://doi.org/10.3109/14767058.2015.1011121
Downloads
Published
How to Cite
Issue
Section
